← NewsAll
Trump unveils TrumpRx.gov for discounted prescription drug prices
Summary
President Trump unveiled TrumpRx.gov, a government-backed website the administration says will display discounted prescription drug prices and generate coupons for participating pharmacies.
Content
President Donald Trump unveiled TrumpRx.gov, a government-backed website intended to provide Americans with discounted prescription drugs. He introduced the site at a White House event alongside Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz and Joe Gebbia, who is advising on design. The administration said the site follows agreements with 16 of the 17 largest pharmaceutical companies under so-called most-favored-nation pricing deals. Officials said participating manufacturers agreed to lower Medicaid prices and extend those reductions to cash-paying consumers through the website.
Key details:
- The president said the United States would pay the lowest price paid by any other country under the agreements and described large percentage reductions.
- The administration said 16 of the 17 largest drugmakers have signed agreements, with the remaining company expected to join.
- Officials described the deals as exchanges in which companies received exemptions from U.S. tariffs and agreed to lower prices for Medicaid and cash purchasers.
- The administration highlighted specific reductions, citing Wegovy falling from more than $1,300 to $199 and an inhaler from $458 to $51, and said average monthly costs were expected in a range of $149 to $350.
- TrumpRx.gov displays discounts, generates a coupon that can be printed or saved to a mobile wallet for use at participating pharmacies, and directs specialty drug purchases to mail-order pharmacies; officials said purchases generally will not count toward insurance deductibles.
Summary:
The administration said discounted prices and the coupon system are available through TrumpRx.gov starting on the day of the announcement. Sixteen of 17 large drugmakers have signed agreements, with the remaining company expected to join. Undetermined at this time.
